CC Chemokine-Mediated Differential Immunoregulation by Human Eosinophils

CC 趋化因子介导的人嗜酸性粒细胞的差异免疫调节

基本信息

  • 批准号:
    9133088
  • 负责人:
  • 金额:
    $ 12.99万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-09-01 至 2019-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The Candidate (Dr. Praveen Akuthota) is a member of the Division of Pulmonary, Critical Care, and Sleep Medicine and of the Division of Allergy and Inflammation at Beth Israel Deaconess Medical Center and is an Instructor in Medicine at Harvard Medical School. This K08 Career Development Award will foster his career goal to become an independent investigator in eosinophil immunobiology. During the award period, the career development plan will allow for the honing of his skills as a basic investigator through carrying out the proposed research under the mentorship of Dr. Peter Weller and through a series of didactic experiences. The environment provided by Beth Israel Deaconess Medical Center and Harvard Medical School is ideally suited for the success of both the research and career development components of the award. The research plan focuses on the immunobiology of human eosinophils. Eosinophils have long been regarded to function exclusively as end-effector cells in asthma and other eosinophilic lung disorders, acting through the release of cytotoxic substances. However, mounting evidence has demonstrated that eosinophils have important multipotent immunoregulatory roles. Characterization of differential immunoregulation by eosinophils has lagged behind that of other immune cell types. This lag may be in part responsible for an incomplete understanding of the pathobiology eosinophilic pulmonary diseases, including asthma. The Candidate's previous work has identified the ligands of CCR7 (CCL19 and CCL21) as chemokines whose impacts on eosinophils and their capacity to influence the local immune environment warrant exploration. The proposed studies will address the overall hypothesis that CCR7 receptor-ligand interactions on eosinophils have an integral role in allergic airways disease that promotes resolution of Th2 inflammation and tissue eosinophilia. To address this overall hypothesis, Specific Aims will investigate the mechanism by which: 1) Human Eosinophils Express a Pro-Resolution Phenotype with CCL19 and CCL21 Stimulation; 2) Human Eosinophils Exposed to CCR7 Ligands Prevent Th2 Polarization of Lymphocytes; 3) Allergic Airway Inflammation Is Increased in Mice with CCR7-Deficient Eosinophils. These studies will utilize human eosinophils isolated from the peripheral blood of human donors and murine models of allergic airways inflammation. Specific experimental designs include multiplex-based studies of cytokine secretion, eosinophil gene expression analysis, eosinophil-lymphocyte interaction studies, and murine studies utilizing eosinophil adoptive transfer. The proposed research has the potential to provide insights into differential eosinophil responses to specific chemokine stimuli and lead to improved understanding of the intersection of eosinophilia and pulmonary disease.
描述(由申请人提供):候选人(Praveen Akuthota博士)是贝斯以色列女执事医疗中心肺部、重症监护和睡眠医学部以及过敏和炎症部的成员,是哈佛医学院的医学讲师。这个K 08职业发展奖将促进他的职业目标,成为嗜酸性粒细胞免疫生物学的独立调查员。在获奖期间,职业发展计划将允许他通过在Peter Weller博士的指导下开展拟议的研究并通过一系列教学经验来磨练他作为基础研究员的技能。贝斯以色列女执事医疗中心和哈佛医学院提供的环境非常适合该奖项的研究和职业发展部分的成功。该研究计划的重点是人类嗜酸性粒细胞的免疫生物学。长期以来,嗜酸性粒细胞一直被认为是哮喘和其他嗜酸性肺疾病中唯一的末端效应细胞,通过释放细胞毒性物质发挥作用。然而,越来越多的证据表明,嗜酸性粒细胞具有重要的多能免疫调节作用。嗜酸性粒细胞差异免疫调节的表征已经落后于其他免疫细胞类型。这种滞后可能是部分负责的病理生物学嗜酸性粒细胞肺疾病,包括哮喘的理解不完全。候选人以前的工作已经确定了CCR 7的配体(CCL 19和CCL 21)作为趋化因子,其对嗜酸性粒细胞的影响及其影响局部免疫环境的能力值得探索。拟议的研究将解决总体假设,即嗜酸性粒细胞上的CCR 7受体-配体相互作用在过敏性气道疾病中具有不可或缺的作用,促进Th 2炎症和组织嗜酸性粒细胞增多的消退。为了解决这一总体假设,Specific Aims将研究以下机制:1)人嗜酸性粒细胞在CCL 19和CCL 21刺激下表达促消退表型; 2)暴露于CCR 7配体的人嗜酸性粒细胞阻止淋巴细胞的Th 2极化; 3)CCR 7缺陷型嗜酸性粒细胞小鼠的过敏性气道炎症增加。这些研究将利用从人供体外周血和过敏性气道炎症小鼠模型中分离的人嗜酸性粒细胞。具体的实验设计包括基于多重的细胞因子分泌研究、嗜酸性粒细胞基因表达分析、嗜酸性粒细胞-淋巴细胞相互作用研究和利用嗜酸性粒细胞过继转移的小鼠研究。拟议的研究有可能提供不同的嗜酸性粒细胞对特定趋化因子刺激的反应的见解,并导致嗜酸性粒细胞增多症和肺部疾病的交叉点的理解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Praveen Akuthota其他文献

Praveen Akuthota的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Praveen Akuthota', 18)}}的其他基金

San Diego Team Asthma Management using Phenotypes (STAMP)
圣地亚哥团队使用表型进行哮喘管理 (STAMP)
  • 批准号:
    10220116
  • 财政年份:
    2017
  • 资助金额:
    $ 12.99万
  • 项目类别:
San Diego Team Asthma Management using Phenotypes (STAMP)
圣地亚哥团队使用表型进行哮喘管理 (STAMP)
  • 批准号:
    9406023
  • 财政年份:
    2017
  • 资助金额:
    $ 12.99万
  • 项目类别:
San Diego Team Asthma Management using Phenotypes (STAMP)
圣地亚哥团队使用表型进行哮喘管理 (STAMP)
  • 批准号:
    10455030
  • 财政年份:
    2017
  • 资助金额:
    $ 12.99万
  • 项目类别:
San Diego Team Asthma Management using Phenotypes (STAMP)
圣地亚哥团队使用表型进行哮喘管理 (STAMP)
  • 批准号:
    9751950
  • 财政年份:
    2017
  • 资助金额:
    $ 12.99万
  • 项目类别:
San Diego Team Asthma Management using Phenotypes (STAMP)
圣地亚哥团队使用表型进行哮喘管理 (STAMP)
  • 批准号:
    9981490
  • 财政年份:
    2017
  • 资助金额:
    $ 12.99万
  • 项目类别:
CC Chemokine-Mediated Differential Immunoregulation by Human Eosinophils
CC 趋化因子介导的人嗜酸性粒细胞的差异免疫调节
  • 批准号:
    9108999
  • 财政年份:
    2015
  • 资助金额:
    $ 12.99万
  • 项目类别:
Tetraspanins in Asthma and Eosinophilic Lung Disease
四跨膜蛋白在哮喘和嗜酸性肺病中的作用
  • 批准号:
    7940983
  • 财政年份:
    2009
  • 资助金额:
    $ 12.99万
  • 项目类别:

相似国自然基金

Chemokine-Gli2信号环路调控肝癌生长的分子机制及其靶点价值
  • 批准号:
    81660467
  • 批准年份:
    2016
  • 资助金额:
    39.0 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

MicroRNA-15a/16-mediated cytokine/chemokine reprogramming in Kupffer cells prevents the development of hepatocellular carcinoma
MicroRNA-15a/16 介导的库普弗细胞细胞因子/趋化因子重编程可预防肝细胞癌的发展
  • 批准号:
    10518314
  • 财政年份:
    2022
  • 资助金额:
    $ 12.99万
  • 项目类别:
MicroRNA-15a/16-mediated cytokine/chemokine reprogramming in Kupffer cells prevents the development of hepatocellular carcinoma
MicroRNA-15a/16 介导的库普弗细胞细胞因子/趋化因子重编程可预防肝细胞癌的发展
  • 批准号:
    10688153
  • 财政年份:
    2022
  • 资助金额:
    $ 12.99万
  • 项目类别:
Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer
趋化因子介导的抗原特异性 T 细胞反应和免疫疗法治疗头颈癌
  • 批准号:
    10396548
  • 财政年份:
    2020
  • 资助金额:
    $ 12.99万
  • 项目类别:
Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer
趋化因子介导的抗原特异性 T 细胞反应和免疫疗法治疗头颈癌
  • 批准号:
    10187548
  • 财政年份:
    2020
  • 资助金额:
    $ 12.99万
  • 项目类别:
Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer
趋化因子介导的抗原特异性 T 细胞反应和免疫疗法治疗头颈癌
  • 批准号:
    10614978
  • 财政年份:
    2020
  • 资助金额:
    $ 12.99万
  • 项目类别:
Inhibition of C-X-C chemokine receptor 2 (CXCR2)-mediated neutrophil recruitment as a targeted therapy in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated lung adenocarcinoma.
抑制 C-X-C 趋化因子受体 2 (CXCR2) 介导的中性粒细胞募集作为 Kirsten 大鼠肉瘤病毒癌基因同源物 (KRAS) 突变肺腺癌的靶向治疗。
  • 批准号:
    428770
  • 财政年份:
    2019
  • 资助金额:
    $ 12.99万
  • 项目类别:
    Studentship Programs
Chemokine-mediated control of anti-tumor immunity in DNA-repair deficient colorectal cancer
DNA 修复缺陷型结直肠癌中趋化因子介导的抗肿瘤免疫控制
  • 批准号:
    388955
  • 财政年份:
    2018
  • 资助金额:
    $ 12.99万
  • 项目类别:
    Operating Grants
Discovery and Characterisation of Novel Tick Evasins as Inhibitors of Chemokine-mediated Inflammation
作为趋化因子介导的炎症抑制剂的新型蜱虫逃逸素的发现和表征
  • 批准号:
    nhmrc : 1140867
  • 财政年份:
    2018
  • 资助金额:
    $ 12.99万
  • 项目类别:
    Project Grants
Discovery and Characterisation of Novel Tick Evasins as Inhibitors of Chemokine-mediated Inflammation
作为趋化因子介导的炎症抑制剂的新型蜱虫逃逸素的发现和表征
  • 批准号:
    nhmrc : GNT1140867
  • 财政年份:
    2018
  • 资助金额:
    $ 12.99万
  • 项目类别:
    Project Grants
Elucidation of resistant mechanism for immunotherapy mediated by MAPK signal-driven chemokine suppression
阐明 MAPK 信号驱动趋化因子抑制介导的免疫治疗耐药机制
  • 批准号:
    17K09652
  • 财政年份:
    2017
  • 资助金额:
    $ 12.99万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了